| Original language | English (US) |
|---|---|
| Pages (from-to) | 820-821 |
| Number of pages | 2 |
| Journal | Acta dermato-venereologica |
| Volume | 99 |
| Issue number | 9 |
| DOIs |
|
| State | Published - Jul 2019 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis : Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. / Yosipovitch, Gil; Soung, Jennifer; Weiss, Jonathan; Muscianisi, Elisa; Meng, Xiangyi; Gilloteau, Isabelle; Elewski, Boni E.
In: Acta dermato-venereologica, Vol. 99, No. 9, 07.2019, p. 820-821.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis
T2 - Patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials
AU - Yosipovitch, Gil
AU - Soung, Jennifer
AU - Weiss, Jonathan
AU - Muscianisi, Elisa
AU - Meng, Xiangyi
AU - Gilloteau, Isabelle
AU - Elewski, Boni E.
N1 - Funding Information: Support for thirdparty writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Conflicts of interest: GY has received grants from Sun Pharma and Pfizer outside the submitted work; honoraria from Bayer, Eli Lilly, Galderma, Menlo, Novartis, Opko, Pfizer, Regeneron, Sanofi, Sienna, Trevi, and UCB; and nonfinancial support from Novartis during the conduct of the study. JS has received speaker honoraria from AbbVie, Actelion, Amgen, Celgene, Lilly, the National Psoriasis Foundation, Novartis, Ortho Dermatologics, and Regeneron; consulting/advisory board honoraria from Leo Pharma, Lilly, and Novartis; and grant/research funding from AbbVie, Actavis, Actelion, Allergan, Boehringer Ingelheim, Cassiopea, Dr. Reddy’s, Galderma, GSK, Janssen, Kadmon, Leo Pharma, Menlo, Novan, Novartis, Ortho Dermatologics, Pfizer, and UCB. JW has received speaker honoraria from AbbVie and Ortho Dermatologics; consulting/advisory board honoraria from Aclaris, Foamix, Galderma, Leo Pharma, and Valeant (Ortho Dermatologics); and grant/research funding support to their institution from AbbVie, Aclaris, Endo International, Foamix, Galderma, Leo Pharma, Moberg Pharma North America, Novartis, Promius Pharma, and Valeant (Ortho Dermatologics). EM, XM, and IG are employees of Novartis. B. EE has received grant/research funding to their university from AbbVie, Boehringer Ingelheim, Celgene, Incyte, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and Valeant (Ortho Dermatologics); and consulting fees from Boehringer Ingelheim, Celgene, Leo Pharma, Lilly, Novartis, Pfizer, Sun Pharma, and Valeant (Ortho Dermatologics). Funding Information: Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Conflicts of interest: GY has received grants from Sun Pharma and Pfizer outside the submitted work; honoraria from Bayer, Eli Lilly, Galderma, Menlo, Novartis, Opko, Pfizer, Regeneron, Sanofi, Sienna, Trevi, and UCB; and nonfinancial support from Novartis during the conduct of the study. JS has received speaker honoraria from AbbVie, Actelion, Amgen, Celgene, Lilly, the National Psoriasis Foundation, Novartis, Ortho Dermatologics, and Regeneron; consulting/advisory board honoraria from Leo Pharma, Lilly, and Novartis; and grant/research funding from AbbVie, Actavis, Actelion, Allergan, Boehringer Ingelheim, Cassiopea, Dr. Reddy?s, Galderma, GSK, Janssen, Kadmon, Leo Pharma, Menlo, Novan, Novartis, Ortho Dermatologics, Pfizer, and UCB. JW has received speaker honoraria from AbbVie and Ortho Dermatologics; consulting/advisory board honoraria from. Aclaris, Foamix, Galderma, Leo Pharma, and Valeant (Ortho Der-matologics); and grant/research funding support to their institution from AbbVie, Aclaris, Endo International, Foamix, Galderma, Leo Pharma, Moberg Pharma North America, Novartis, Promius Pharma, and Valeant (Ortho Dermatologics). EM, XM, and IG are employees of Novartis. B. EE has received grant/research funding to their university from AbbVie, Boehringer Ingelheim, Celgene, Incyte, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and Valeant (Ortho Dermatologics); and consulting fees from Boehringer Ingelheim, Celgene, Leo Pharma, Lilly, Novartis, Pfizer, Sun Pharma, and Valeant (Ortho Dermatologics).
PY - 2019/7
Y1 - 2019/7
UR - http://www.scopus.com/inward/record.url?scp=85069889535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069889535&partnerID=8YFLogxK
U2 - 10.2340/00015555-3195
DO - 10.2340/00015555-3195
M3 - Comment/debate
C2 - 31017248
AN - SCOPUS:85069889535
VL - 99
SP - 820
EP - 821
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
IS - 9
ER -